The future of therapy for nonseminomatous germ cell tumors.
暂无分享,去创建一个
[1] C. Cordon-Cardo,et al. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Bartek,et al. p53 Protein alterations in human testicular cancer including pre‐invasive intratubular germ‐cell neoplasia , 1991, International journal of cancer.
[3] L. Einhorn,et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Cordon-Cardo,et al. Blood group-related antigens in human germ cell tumors. , 1988, Cancer research.
[5] S. Fosså,et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T J Yao,et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Tricot,et al. Long-Term Outcome of Patients with Relapsed and Refractory Germ Cell Tumors Treated with High-Dose Chemotherapy and Autologous Bone Marrow Rescue , 1992, Annals of Internal Medicine.
[8] C. Bokemeyer,et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Motzer,et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Einhorn,et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] V. Reuter,et al. Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[12] J. Masters,et al. DNA Repair capacity and cisplatin sensitivity of human testis tumour cells , 1997, International journal of cancer.
[13] G. T. te Meerman,et al. Pathogenesis of adult testicular germ cell tumors. A cytogenetic model. , 1990, Cancer genetics and cytogenetics.
[14] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[15] M. Ladanyi,et al. Leukemic differentiation of a mediastinal germ cell tumor , 1989, Genes, chromosomes & cancer.
[16] R. Chaganti,et al. Genetics and biology of adult human male germ cell tumors. , 2000, Cancer research.
[17] H. Dosaka-akita,et al. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome , 1999, British Journal of Cancer.
[18] R. Motzer,et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Dmitrovsky,et al. The role of ifosfamide plus cisplatin‐based chemotherapy as salvage therapy for patients with refractory germ cell tumors , 1990, Cancer.
[20] R. Gelber,et al. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. , 1998, Journal of Clinical Oncology.
[21] L. Einhorn,et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R Sylvester,et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Yongjiang Ma,et al. p53 Gene Mutations in Chinese Human Testicular Seminoma , 1993 .
[24] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[25] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[26] R. Motzer,et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Chaganti,et al. Cytogenetics of male germ-cell tumors. , 1993, The Urologic clinics of North America.
[28] L. Collette,et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] E. R. Meyts,et al. Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours , 1994 .
[30] V. Reuter,et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. , 1998, Cancer research.
[31] K. Cornetta,et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Birnbaum,et al. Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. , 1995, British Journal of Cancer.
[33] C. Cordon-Cardo,et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.
[34] R. Motzer,et al. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] V. Reuter,et al. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[36] Michael E. Cohen,et al. The influence and reliability of neurologic assessment and karnofsky performance score on prognosis , 1985, Cancer.
[37] M. Bains,et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Loveland,et al. Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. , 1997, The Journal of endocrinology.
[39] T. Ulbright,et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] F. Perera,et al. Platinum‐DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme‐linked immunosorbent assay , 1994, Cancer.
[41] L. Norton,et al. The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.
[42] R. Motzer,et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] E. Schmidt,et al. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[44] C. Bokemeyer,et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] P. Meltzer,et al. Molecular cytogenetic analysis of i(12p)‐negative human male germ cell tumors , 1993, Genes, chromosomes & cancer.
[46] M. Stockler,et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial , 2001, The Lancet.
[47] A. Levine,et al. A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation , 1996, Nature Medicine.
[48] R. Motzer,et al. Metastatic germ cell tumors: modeling for response to chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Serth,et al. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis , 1996, Cancer.
[50] G. Evan,et al. Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.
[51] S. Baltacı,et al. P53, bcl‐2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours , 2001, BJU international.
[52] H. Joensuu,et al. Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours , 2001, Annals of medicine.
[53] L. Einhorn,et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support , 1994, Cancer.
[54] N. Geller,et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] V. Reuter,et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation , 1998, Oncogene.
[56] C. Chresta,et al. Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis , 1999, Oncogene.
[57] V. Reuter,et al. Loss of heterozygosity and decreased expression of NME genes correlate with teratomatous differentiation in human male germ cell tumors. , 1994, Biochemical and biophysical research communications.
[58] J. Oosterhuis,et al. Cytogenetics of carcinoma in situ of the testis. , 1990, Cancer genetics and cytogenetics.
[59] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[60] J. Moul,et al. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[61] Richard Sylvester,et al. International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .
[62] V. Reuter,et al. Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. , 1992, Cancer research.
[63] R. Motzer,et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. , 1998, The Journal of urology.
[64] W. Siegert,et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] L. Schwartz,et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] R. Motzer,et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] A. Ullrich,et al. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. , 1991, Cancer research.
[68] M. Bains,et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] C. Bokemeyer,et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[70] C. Chresta,et al. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. , 1996, Cancer research.
[71] N. Geller,et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] J. Moul,et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. , 1995, The Journal of urology.
[73] R. Motzer,et al. Clinical Relevance of the i(12p) Chromosome in Germ cell Tumors , 1994 .
[74] E. D. de Vries,et al. Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line , 1998, Cancer Chemotherapy and Pharmacology.
[75] Y. Geng,et al. Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.
[76] S. Williams,et al. Phase II trial of gemcitabine in refractory germ cell tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] L. Einhorn,et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] P. Catalano,et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.